GDF11

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Retrieved on: 
Tuesday, February 6, 2024
Biotechnology, Health, Fitness & Nutrition, Pharmaceutical, Clinical Trials, Poster, Weight loss, Pharmacokinetics, Human, Investigational New Drug, Obesity, Patient, IND, Fasting, Keystone, Myostatin, GDF11, Mouse, Rock, MPH, Food, SMA, Body composition, Immunoglobulin G, Nandi (Hinduism), Doctor of Philosophy, Liraglutide, ELISA, Dietary supplement

“These preclinical data showing that SRK-439 preserves lean mass and improves fat mass loss provide compelling scientific rationale to study SRK-439 in combination with GLP-1 RA therapies for healthy weight loss management,” said Jay Backstrom, M.D., MPH, President and CEO of Scholar Rock.

Key Points: 
  • “These preclinical data showing that SRK-439 preserves lean mass and improves fat mass loss provide compelling scientific rationale to study SRK-439 in combination with GLP-1 RA therapies for healthy weight loss management,” said Jay Backstrom, M.D., MPH, President and CEO of Scholar Rock.
  • “We believe that preserving lean muscle mass through our highly selective approach to myostatin inhibition in combination with GLP-1 RA therapy has the potential to transform the management of weight loss.
  • In parallel, Scholar Rock is developing SRK-439, a novel investigational selective myostatin inhibitor, optimized for the treatment of obesity.
  • SRK-439 also improved fat mass loss (–36.60% to –46.32% from baseline with semaglutide; –17.31% to –19.04% from baseline with liraglutide).

Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference

Retrieved on: 
Monday, May 22, 2023
GDF11, Mouse, Endothelial dysfunction, Heart failure, TGF, Heart, PAH, Serum, ATS, Matrix metalloproteinase inhibitor, Cardiac fibrosis, SMAD, Pharmacokinetics, Woman, IL-6, Research, Part, Inflammation, Biomarker, American Thoracic Society, SMAD2, Administration, TAC, MARCO, Asilomar International Conference on Climate Intervention Technologies, Patient, Vascular remodelling in the embryo, Orthostatic hypertension, Therapy, Hypoxia, Conference, Endothelium, Safety, KROS, Pharmaceutical industry, Medical device, Extractive metallurgy, Vaccine, Trapping, Fibrosis

“We are pleased to present clinical and preclinical data from our KER-012 program at the ATS conference this year.

Key Points: 
  • “We are pleased to present clinical and preclinical data from our KER-012 program at the ATS conference this year.
  • The preclinical presentations demonstrate observed ligand selectivity of KER-012 and changes in inflammation and fibrosis in models of PAH and cardiovascular diseases.
  • Keros reported preliminary topline data from the Part 1 single ascending dose portion of the trial in May 2022, and additional preliminary clinical data from the Part 2 multiple ascending dose portion of the trial in September 2022.
  • HPAECs and HPASMCs were treated with activin A, GDF11, or bone morphogenetic protein 9 (“BMP9”) in the presence of KER-012.

Versanis Presents Preclinical Data Demonstrating the Potential of Bimagrumab as a Novel Obesity Treatment at ObesityWeek 2022

Retrieved on: 
Wednesday, November 2, 2022
Atlas Venture, Waist, Weakness, Mouse, Bimagrumab, Myostatin, Incretin, Obesity, Ligand, Body composition, Safety, GDF11, Activin and inhibin, Atlas, Human, Muscle, Patient, Multimedia, Therapy, Pharmaceutical industry, Dietary supplement

NEW YORK, Nov. 2, 2022 /PRNewswire/ -- Versanis Bio ("Versanis"), a clinical-stage biopharmaceutical company advancing novel therapeutics for cardiometabolic diseases, today shares new preclinical data reaffirming the potential of lead asset bimagrumab as a novel obesity treatment at ObesityWeek 2022, hosted November 1-4 in San Diego. The new preclinical results highlight the therapeutic potential of bimagrumab as a monotherapy and also when co-administered with incretin therapies in people living with obesity.

Key Points: 
  • NEW YORK, Nov. 2, 2022 /PRNewswire/ --Versanis Bio ("Versanis"), a clinical-stage biopharmaceuticalcompany advancing novel therapeutics for cardiometabolic diseases, today shares new preclinical data reaffirming the potential of lead asset bimagrumab as a novel obesity treatment at ObesityWeek 2022, hosted November 1-4 in San Diego.
  • The new preclinical results highlight the therapeutic potential of bimagrumab as a monotherapy and also when co-administered with incretin therapies in people living with obesity.
  • Experiments in a diet-induced obesity model in mice showed that the mouse version of bimagrumab elicited fat mass loss and lean mass gain.
  • "These data reported today at ObesityWeek contribute to the growing body of preclinical and clinical data that support our upcoming Phase 2b study of bimagrumab in patients living with obesity."

Versanis Bio Appoints Kenneth Attie, M.D., and Aditya Venugopal, Ph.D., to Key Leadership Roles

Retrieved on: 
Tuesday, October 18, 2022
Cornell University, Kaiser San Francisco Medical Center, Doctor of Philosophy, Bimagrumab, Therapy, Strategic planning, Activin and inhibin, Muscle, Intercept Pharmaceuticals, Medical research, Lists of diseases, Myostatin, Ligand, Biotechnology, Patient, Insming, Business, Genentech, Program, Fatty liver disease, Venugopal, GDF11, Body composition, New York University Grossman School of Medicine, Immunoglobulin G, Multimedia, Technology, Senior, NASH, University, NEW, Acquisition, Atlas, Obesity, Acceleron Pharma, Business development, University of California, Corporate development, Neuromuscular Disorders, Luspatercept, Atlas Venture, Hematology, Metabolism, Navigant Consulting, View, Management, Pharmaceutical industry, Medicine, New York University

NEW YORK, Oct. 18, 2022 /PRNewswire/ -- Versanis Bio ("Versanis"), a clinical stage company advancing novel therapeutics for people living with obesity and cardiometabolic diseases, today announced two key leadership appointments. Versanis welcomed Executive Vice President and Chief Medical Officer, Kenneth Attie, M.D., and Senior Vice President, Corporate Development and Strategic Planning, Aditya Venugopal, Ph.D.

Key Points: 
  • Versanis welcomedExecutive Vice President and Chief Medical Officer, Kenneth Attie, M.D., and Senior Vice President, Corporate Development and Strategic Planning, Aditya Venugopal, Ph.D.
    "Ken and Aditya each have demonstrated success growing biotechnology companies," said Versanis CEO Mark Pruzanski, M.D.
  • He also held leadership roles at Altus Pharmaceuticals and Insmed and spent more than a decade at Genentech.
  • Versanis Bio is a privately held, clinical-stage biopharmaceutical company bringing transformational treatments to people living with cardiometabolic disease.
  • Versanis was founded in 2021 and is a portfolio company of Aditum Bio, Atlas Venture, and Medicxi.

Versanis Bio Announces Leadership and Board Appointments as Company Prepares to Initiate Phase 2b Study with Novel Approach to Obesity

Retrieved on: 
Wednesday, July 20, 2022
Intercept, Body composition, University, Biogen, Weight, Obesity, Overweight, Wharton School of the University of Pennsylvania, Industry, Atlas, Myostatin, CEO, Executive, Lists of companies, Health, NASH, RNA interference, Intercept Pharmaceuticals, Board, Activin and inhibin, Type 2 diabetes, Wendell Pritchett, Atlas Venture, Biotechnology, DOV Pharmaceutical, Director, MBA, Chicago (franchise), Disease, Biochemistry, Patient, Liver failure, McMaster University Medical School, Doctor of Philosophy, Bimagrumab, Therapy, Chronic liver disease, Program, Ligand, Biotechnology Innovation Organization, International relations, Molecular biology, SAB, GDF11, Johns Hopkins University, BIO, Takeda Oncology, Management, Pharmaceutical industry, Dietary supplement, ZymoGenetics, Alnylam Pharmaceuticals

NEW YORK, July 20, 2022 /PRNewswire/ -- Versanis Bio ("Versanis"), a clinical-stage company advancing novel therapeutics for cardiometabolic diseases, today announced three organizational appointments. Versanis welcomes Mark Pruzanski, M.D., as Chairman and Chief Executive Officer, and John Maraganore, Ph.D., and Barbara Duncan, MBA, to the Board of Directors. Lloyd Klickstein, M.D., Ph.D., who co-founded the company in 2021 with Aditum Bio, will continue in the role of President and Chief Scientific Officer.

Key Points: 
  • NEW YORK, July 20, 2022 /PRNewswire/ -- Versanis Bio ("Versanis"), a clinical-stage company advancing novel therapeutics for cardiometabolic diseases, today announced three organizational appointments.
  • Versanis is advancing its lead asset bimagrumab, a first-in-class monoclonal antibody that binds activin type II receptors, into a Phase 2b study later this year for the initial indication of obesity.
  • Versanis is a privately held, clinical-stage biopharmaceutical company bringing transformational treatments to people living with cardiometabolic disease.
  • Versanis was founded in 2021 and is a portfolio company of Aditum Bio, Atlas Venture and Medicxi.

Elevian Adds Stroke Clinical Advisory Team

Retrieved on: 
Tuesday, February 9, 2021
Medical specialties, Health, GDF11, Stroke, Occupational therapy

ALLSTON, Mass., Feb. 9, 2021 /PRNewswire/ -- Elevian , an emerging biotech company developing new medicines that target the GDF11 pathway, announced the addition of a stroke clinical advisory team to advance development of recombinant GDF11 (rGDF11) to promote recovery post stroke.

Key Points: 
  • ALLSTON, Mass., Feb. 9, 2021 /PRNewswire/ -- Elevian , an emerging biotech company developing new medicines that target the GDF11 pathway, announced the addition of a stroke clinical advisory team to advance development of recombinant GDF11 (rGDF11) to promote recovery post stroke.
  • "We have assembled several of the leading experts in the emerging field of stroke recovery, bringing together knowledge and experience about the clinical implications of stroke and emerging therapies," said Mark Allen, M.D., CEO of Elevian.
  • "Elevian has produced exciting preclinical efficacy data demonstrating that rGDF11 promotes motor function recovery post stroke.
  • Dr. Cramer has been awarded the Stroke Rehabilitation Award from the American Heart Association and the Barbro B. Johansson Award in Stroke Recovery from the World Stroke Organization.

Elevian Adds Deep Scientific and Business Expertise

Retrieved on: 
Tuesday, January 26, 2021
Health sciences, GDF11, Health, Acumen, Clinical trial, Branches of biology

"Mr. Curhan's deep experience as CFO and investment banker provides Elevian with astute financial acumen.

Key Points: 
  • "Mr. Curhan's deep experience as CFO and investment banker provides Elevian with astute financial acumen.
  • Dr. Dale's deep experience in protein manufacturing will help Elevian to scale production of GDF11 as we move toward clinical trials.
  • Mr. Leslie and Mr. Robbins will help us to create a valuable and enduring business as we pursue our mission to promote healthy aging and treat age-related diseases.
  • We look forward to the guidance and contribution of each in advancing Elevian."

Elevian Announces $15 Million Equity Financing

Retrieved on: 
Tuesday, November 24, 2020
GDF11, Biotechnology, Biology, Life sciences

ALLSTON, Mass., Nov. 24, 2020 /PRNewswire/ -- Elevian , an emerging biotech company developing medicines that restore youthful regenerative capacity with the potential to treat and prevent multiple age-related diseases, today announced the closing of a $15 million equity financing.

Key Points: 
  • ALLSTON, Mass., Nov. 24, 2020 /PRNewswire/ -- Elevian , an emerging biotech company developing medicines that restore youthful regenerative capacity with the potential to treat and prevent multiple age-related diseases, today announced the closing of a $15 million equity financing.
  • Proceeds from the equity financing will enable Elevian to advance recombinant GDF11 (rGDF11) toward the clinic to treat stroke and other age-related diseases.
  • In conjunction with the financing, Elevian has appointed Suzanne Fletcher and Dan Marshak to its board of directors.
  • Elevian is an emerging biotech company developing medicines that restore youthful regenerative capacity, with the potential to treat and prevent multiple age-related diseases.

Elevian Launches to Develop Regenerative Medicines for Age-Related Diseases

Retrieved on: 
Thursday, September 6, 2018
GDF11, Biology, Natural environment, Regenerative design, Drug, Medication, Nature

SAN FRANCISCO, Sept. 6, 2018 /PRNewswire/ -- Elevian, a new company developing medicines that restore youthful regenerative capacity, with the potential to treat and prevent age-related disease, launches at TechCrunch Disrupt's Startup Battlefield.

Key Points: 
  • SAN FRANCISCO, Sept. 6, 2018 /PRNewswire/ -- Elevian, a new company developing medicines that restore youthful regenerative capacity, with the potential to treat and prevent age-related disease, launches at TechCrunch Disrupt's Startup Battlefield.
  • Mark Allen, MD, Co-founder, CEO
    Elevian's founders, working at Stanford and then Harvard, discovered the regenerative effects of young blood.
  • Based on this, Elevian is developing new medicines that increase the activity levels of GDF11 to potentially prevent and treat age-related diseases.
  • Elevian is on a path to make commercially viable drugs to treat major diseases of aging.